Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $883 Billion
  • Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,509,325 shares of AKRO stock, worth $217 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,509,325
Previous 4,817,091 6.39%
Holding current value
$217 Million
Previous $195 Million 23.4%
% of portfolio
0.03%
Previous 0.02%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
SELL
$34.04 - $56.28 $10.5 Million - $17.3 Million
-307,766 Reduced 6.39%
4,509,325 $241 Million
Q1 2025

May 14, 2025
BUY
$21.87 - $57.56 $10.8 Million - $28.5 Million
495,119 Added 11.46%
4,817,091 $195 Million
Q4 2024

Feb 14, 2025
BUY
$26.75 - $35.28 $13.7 Million - $18.1 Million
513,613 Added 13.49%
4,321,972 $120 Million
Q3 2024

Nov 14, 2024
SELL
$21.45 - $29.34 $7.25 Million - $9.92 Million
-337,992 Reduced 8.15%
3,808,359 $109 Million
Q2 2024

Aug 14, 2024
BUY
$18.31 - $24.62 $1.57 Million - $2.11 Million
85,872 Added 2.11%
4,146,351 $97.3 Million
Q1 2024

May 15, 2024
BUY
$17.76 - $31.18 $6.83 Million - $12 Million
384,555 Added 10.46%
4,060,479 $103 Million
Q4 2023

Feb 14, 2024
SELL
$11.38 - $50.33 $1.53 Million - $6.76 Million
-134,270 Reduced 3.52%
3,675,924 $85.8 Million
Q3 2023

Nov 14, 2023
BUY
$41.19 - $52.25 $21.4 Million - $27.2 Million
520,551 Added 15.82%
3,810,194 $193 Million
Q2 2023

Aug 14, 2023
BUY
$36.89 - $56.88 $24.6 Million - $37.9 Million
665,963 Added 25.38%
3,289,643 $154 Million
Q1 2023

May 15, 2023
BUY
$37.27 - $50.24 $8.3 Million - $11.2 Million
222,643 Added 9.27%
2,623,680 $100 Million
Q4 2022

Feb 14, 2023
BUY
$33.44 - $54.8 $31.4 Million - $51.4 Million
938,613 Added 64.18%
2,401,037 $132 Million
Q3 2022

Nov 14, 2022
BUY
$10.15 - $34.05 $10.2 Million - $34.3 Million
1,007,122 Added 221.2%
1,462,424 $49.8 Million
Q2 2022

Aug 15, 2022
SELL
$8.0 - $15.01 $496 - $930
-62 Reduced 0.01%
455,302 $4.3 Million
Q1 2022

May 16, 2022
SELL
$12.97 - $22.26 $9.13 Million - $15.7 Million
-704,166 Reduced 60.73%
455,364 $6.46 Million
Q4 2021

Feb 14, 2022
BUY
$19.87 - $26.24 $157,588 - $208,109
7,931 Added 0.69%
1,159,530 $24.5 Million
Q3 2021

Nov 15, 2021
SELL
$18.65 - $25.46 $48,564 - $66,297
-2,604 Reduced 0.23%
1,151,599 $25.7 Million
Q2 2021

Aug 16, 2021
BUY
$24.81 - $32.35 $6.48 Million - $8.45 Million
261,057 Added 29.23%
1,154,203 $28.6 Million
Q1 2021

May 17, 2021
BUY
$24.04 - $34.19 $5.67 Million - $8.06 Million
235,691 Added 35.85%
893,146 $25.9 Million
Q4 2020

Feb 16, 2021
BUY
$25.12 - $29.89 $16.5 Million - $19.7 Million
657,455 New
657,455 $17 Million

Others Institutions Holding AKRO

# of Institutions
298
Shares Held
92.2M
Call Options Held
1.72M
Put Options Held
923K
View Full List

About Akero Therapeutics, Inc.

AKRO Quotes by TradingView
  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.23B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email